
Andrew W Lloyd

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8511647/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Vandetanib-eluting radiopaque beads for chemoembolization: physicochemical evaluation and biological activity of vandetanib in hypoxia. Anti-Cancer Drugs, 2021, 32, 897-908.	0.7	Ο
2	Predicting pharmacokinetic behaviour of drug release from drug-eluting embolization beads using in vitro elution methods. European Journal of Pharmaceutical Sciences, 2019, 136, 104943.	1.9	23
3	Possible mineral contributions to the diet and health of wild chimpanzees in three East African forests. American Journal of Primatology, 2019, 81, e22978.	0.8	7
4	Preparation and characterisation of vandetanib-eluting radiopaque beads for locoregional treatment of hepatic malignancies. European Journal of Pharmaceutical Sciences, 2017, 101, 22-30.	1.9	27
5	Unusual behaviour induced by phase separation in hydrogel microspheres. Acta Biomaterialia, 2017, 53, 190-198.	4.1	5
6	Towards Hypoxia-responsive Drug-eluting Embolization Beads. International Journal of Pharmaceutics, 2017, 524, 226-237.	2.6	2
7	Hypoxia as a target for drug combination therapy of liver cancer. Anti-Cancer Drugs, 2017, 28, 771-780.	0.7	29
8	Synthesis and characterisation of cationic quaternary ammonium-modified polyvinyl alcohol hydrogel beads as a drug delivery embolisation system. Journal of Materials Science: Materials in Medicine, 2016, 27, 53.	1.7	10
9	Mineral Acquisition from Clay by Budongo Forest Chimpanzees. PLoS ONE, 2015, 10, e0134075.	1.1	25
10	Nanoprecipitation of polymeric nanoparticle micelles based on 2-methacryloyloxyethyl phosphorylcholine (MPC) with 2-(diisopropylamino)ethyl methacrylate (DPA), for intracellular delivery applications. Journal of Materials Science: Materials in Medicine, 2015, 26, 150.	1.7	16
11	3D Artificial Nanodiamonds Containing Nanocomposites Based on Hybrid Polyurethane-Poly(2-Hydroxyethyl Methacrylate) Polymer Matrix. Springer Proceedings in Physics, 2015, , 149-164.	0.1	2
12	Examining porous bio-active glass as a potential osteo-odonto-keratoprosthetic skirt material. Journal of Materials Science: Materials in Medicine, 2013, 24, 1217-1227.	1.7	24
13	The role of interfacial chemistry and interactions in the dynamics of thermosetting polyurethane‑multiwalled carbon nanotube composites at low filler contents. Colloid and Polymer Science, 2013, 291, 573-583.	1.0	22
14	Development of a combination drug-eluting bead. Anti-Cancer Drugs, 2012, 23, 355-369.	0.7	16
15	Gradient semi-interpenetrating polymer networks based on polyurethane and poly(2-hydroxyethyl) Tj ETQq1 1	0.784314 r 6.7	gBT /Overlock
16	Microstructure changes of polyurethane by inclusion of chemically modified carbon nanotubes at low filler contents. Composites Science and Technology, 2012, 72, 865-872.	3.8	38
17	A Comparison of Glycine, Sarcosine, N,N-Dimethylglycine, Glycinebetaine and N-Modified Betaines as Liposome Cryoprotectants. Journal of Pharmacy and Pharmacology, 2011, 44, 507-511.	1.2	24
18	Optimization of the Chiral Inversion of 2-Phenylpropionic Acid by Verticillium lecanii. Journal of Pharmacy and Pharmacology, 2011, 49, 263-269.	1.2	3

#	Article	IF	CITATIONS
19	The Synthesis and Comparison of Modified Betaines as Cryoprotective Agents. Journal of Pharmacy and Pharmacology, 2011, 42, 75P-75P.	1.2	1
20	A Study of Modified Betaines as Cryoprotective Additives. Journal of Pharmacy and Pharmacology, 2011, 46, 704-707.	1.2	22
21	The Effect of Cryoprotective Additives on the Zeta Potential of Liposomes. Journal of Pharmacy and Pharmacology, 2011, 42, 143P-143P.	1.2	3
22	Effects of oxygen plasma treatment on the surface wettability and dissolution of furosemide compacts. Journal of Pharmacy and Pharmacology, 2010, 55, 1473-1478.	1.2	2
23	Characterisation of physico-mechanical properties and degradation potential of calcium alginate beads for use in embolisation. Journal of Materials Science: Materials in Medicine, 2010, 21, 2243-2251.	1.7	50
24	Comparison of DC Bead-irinotecan and DC Bead-topotecan drug eluting beads for use in locoregional drug delivery to treat pancreatic cancer. Journal of Materials Science: Materials in Medicine, 2010, 21, 2683-2690.	1.7	32
25	Towards a synthetic osteo-odonto-keratoprosthesis. Acta Biomaterialia, 2009, 5, 438-452.	4.1	32
26	The in vitro corneal biocompatibility of hydroxyapatite coated carbon mesh. Biomaterials, 2009, 30, 3143-3149.	5.7	28
27	The cytotoxicity of highly porous medical carbon adsorbents. Carbon, 2009, 47, 1887-1895.	5.4	15
28	Decaying Raphia farinifera Palm Trees Provide a Source of Sodium for Wild Chimpanzees in the Budongo Forest, Uganda. PLoS ONE, 2009, 4, e6194.	1.1	29
29	Inflammatory cytokine removal by an activated carbon device in a flowing system. Biomaterials, 2008, 29, 1638-1644.	5.7	34
30	Doxorubicin eluting beads—2: methods for evaluating drug elution and in-vitro:in-vivo correlation. Journal of Materials Science: Materials in Medicine, 2008, 19, 767-775.	1.7	115
31	Sonoelectrochemical deposition of calcium phosphates on carbon materials: effect of current density. Journal of Materials Science: Materials in Medicine, 2008, 19, 1787-1791.	1.7	15
32	Sonoelectrochemical deposition of calcium phosphate coatings on carbon materials—effect of electrolyte concentration. Journal of Materials Science: Materials in Medicine, 2008, 19, 2845-2850.	1.7	6
33	Phase separation in the polyurethane/poly(2â€hydroxyethyl methacrylate) semiâ€interpenetrating polymer networks synthesized by different ways. Polymer Engineering and Science, 2008, 48, 588-597.	1.5	21
34	Polymeric hydrogels for novel contact lens-based ophthalmic drug delivery systems: A review. Contact Lens and Anterior Eye, 2008, 31, 57-64.	0.8	254
35	In vitro cytotoxicity assessment of carbon fabric coated with calcium phosphate. New Carbon Materials, 2008, 23, 139-143.	2.9	15
36	Calcium phosphate sonoelectrodeposition on carbon fabrics and its effect on osteoblast cell viability in vitro. New Carbon Materials, 2007, 22, 121-125.	2.9	28

#	Article	IF	CITATIONS
37	Cell behaviour on phospholipids-coated surfaces. Journal of Materials Science: Materials in Medicine, 2007, 18, 611-617.	1.7	23
38	Doxorubicin eluting beads â~ 1: Effects of drug loading on bead characteristics and drug distribution. Journal of Materials Science: Materials in Medicine, 2007, 18, 1691-1699.	1.7	158
39	DC Bead: In Vitro Characterization of a Drug-delivery Device for Transarterial Chemoembolization. Journal of Vascular and Interventional Radiology, 2006, 17, 335-342.	0.2	383
40	Calcium-binding phospholipids as a coating material for implant osteointegration. Journal of the Royal Society Interface, 2006, 3, 277-281.	1.5	23
41	Polyurethane/poly(hydroxyethyl methacrylate) semi-interpenetrating polymer networks for biomedical applications. Journal of Materials Science: Materials in Medicine, 2006, 17, 1283-1296.	1.7	29
42	In vivo assessment of the osteointegrative potential of phosphatidylserine-based coatings. Journal of Materials Science: Materials in Medicine, 2006, 17, 789-794.	1.7	22
43	The in vitro adsorption of cytokines by polymer-pyrolysed carbon. Biomaterials, 2006, 27, 5286-5291.	5.7	38
44	Mesoporous carbide-derived carbon with porosity tuned for efficient adsorption of cytokines. Biomaterials, 2006, 27, 5755-5762.	5.7	119
45	Assessing the in vitro biocompatibility of a novel carbon device for the treatment of sepsis. Biomaterials, 2005, 26, 7124-7131.	5.7	28
46	Novel biocompatible phosphorylcholine-based self-assembled nanoparticles for drug delivery. Journal of Controlled Release, 2005, 104, 259-270.	4.8	76
47	Effects of phosphatidylserine coatings on titanium on inflammatory cells and cell-induced mineralisation in vitro. Biomaterials, 2005, 26, 7572-7578.	5.7	24
48	Bacterial adhesion to bisphosphonate coated hydroxyapatite. Journal of Materials Science: Materials in Medicine, 2005, 16, 283-287.	1.7	47
49	Bacterial adhesion to phosphorylcholine-based polymers with varying cationic charge and the effect of heparin pre-adsorption. Journal of Materials Science: Materials in Medicine, 2005, 16, 1003-1015.	1.7	33
50	Gradient semi-interpenetrating polymer networks based on polyurethane and poly(vinyl pyrrolidone). Journal of Materials Chemistry, 2005, 15, 499.	6.7	30
51	The Osteo-Odonto-Keratoprosthesis (OOKP). Seminars in Ophthalmology, 2005, 20, 113-128.	0.8	134
52	Synthesis and Characterization of Biocompatible Thermo-Responsive Gelators Based on ABA Triblock Copolymers. Biomacromolecules, 2005, 6, 994-999.	2.6	164
53	Fibrinogen adsorption and platelet adhesion to metal and carbon coatings. Thrombosis and Haemostasis, 2004, 92, 1032-1039.	1.8	38
54	In vitro host response assessment of biomaterials for cardiovascular stent manufacture. Journal of Materials Science: Materials in Medicine, 2004, 15, 473-477.	1.7	38

#	Article	IF	CITATIONS
55	Biological responses to cationically charged phosphorylcholine-based materials in vitro. Biomaterials, 2004, 25, 5125-5135.	5.7	50
56	Furanone-based antibacterial coatings. Materials Today, 2004, 7, 23.	8.3	0
57	The effect of phosphorylcholine-coated materials on the inflammatory response and fibrous capsule formation:In vitro andin vivo observations. Journal of Biomedical Materials Research Part B, 2004, 68A, 1-9.	3.0	57
58	Effects of plasma irradiation on the wettability and dissolution of compacts of griseofulvin. International Journal of Pharmaceutics, 2004, 269, 443-450.	2.6	38
59	The biocompatibility of crosslinkable copolymer coatings containing sulfobetaines and phosphobetaines. Biomaterials, 2004, 25, 1195-1204.	5.7	134
60	Biological evaluation and drug delivery application of cationically modified phospholipid polymers. Biomaterials, 2004, 25, 4785-4796.	5.7	41
61	The effect of protein binding on ibuprofen adsorption to activated carbons. Carbon, 2004, 42, 565-571.	5.4	20
62	Structural Characteristics of Activated Carbons and Ibuprofen Adsorption Affected by Bovine Serum Albumin. Langmuir, 2004, 20, 2837-2851.	1.6	42
63	Methods to quantify the biotin-binding capacity of streptavidin-coated polypropylene PCR plates. Biotechnology Letters, 2003, 25, 1325-1328.	1.1	5
64	Developments in microarray technologies. Drug Discovery Today, 2003, 8, 642-651.	3.2	98
65	Controlled biological response on blends of a phosphorylcholine-based copolymer with poly(butyl) Tj ETQq1 1 0.	784314 rg	gBT_/Overlock 42
66	A model for the preliminary biological screening of potential keratoprosthetic biomaterials. Biomaterials, 2003, 24, 4729-4739.	5.7	19
67	Well-Defined Biocompatible Block Copolymers via Atom Transfer Radical Polymerization of 2-Methacryloyloxyethyl Phosphorylcholine in Protic Media. Macromolecules, 2003, 36, 3475-3484.	2.2	216
68	Opacification of SC60B-OUV lens implant following routine phacoemulsification surgery: case report and EM study. British Journal of Ophthalmology, 2003, 87, 800-801.	2.1	2
69	Serum Protein Absorption on Silk Fibroin Fibers and Films: Surface Opsonization and Binding Strength. Journal of Bioactive and Compatible Polymers, 2002, 17, 23-35.	0.8	37
70	Domain-Driven Binding of Fibrin(Ogen) onto Silk Fibroin Biomaterials. Journal of Bioactive and Compatible Polymers, 2002, 17, 195-208.	0.8	14
71	Corneal toxicity secondary to inadvertent use of benzalkonium chloride preserved viscoelastic material in cataract surgery. British Journal of Ophthalmology, 2002, 86, 299-305.	2.1	60
72	CORNEAL TOXICITY SECONDARY TO INADVERTENT USE OF BENZALKONIUM CHLORIDE PRESERVED VISCOELASTIC MATERIAL IN CATARACT SURGERY. Evidence-Based Eye Care, 2002, 3, 184-185.	0.2	1

#	Article	IF	CITATIONS
73	Synthesis of Biocompatible Polymers. 1. Homopolymerization of 2-Methacryloyloxyethyl Phosphorylcholine via ATRP in Protic Solvents:  An Optimization Study. Macromolecules, 2002, 35, 9306-9314.	2.2	161
74	The interactions of bisphosphonates in solution and as coatings on hydroxyapatite with osteoblasts. Journal of Materials Science: Materials in Medicine, 2002, 13, 923-931.	1.7	16
75	Applications of radio frequency cold plasma treatment of polypropylene PCR plates. Biotechnology Letters, 2002, 24, 2071-2074.	1.1	4
76	Interfacial bioengineering to enhance surface biocompatibility. Medical Device Technology, 2002, 13, 18-21.	0.1	14
77	Volume-Activated Chloride Currents in HeLa Cells are Blocked by Tamoxifen But Not by a Membrane Impermeant Quaternary Analogue. Cellular Physiology and Biochemistry, 2001, 11, 99-104.	1.1	12
78	Experimental flow studies in glaucoma drainage device development. British Journal of Ophthalmology, 2001, 85, 1231-1236.	2.1	25
79	Ocular biomaterials and implants. Biomaterials, 2001, 22, 769-785.	5.7	271
80	A comparison of the use of an ATP-based bioluminescent assay and image analysis for the assessment of bacterial adhesion to standard HEMA and biomimetic soft contact lenses. Biomaterials, 2001, 22, 3225-3233.	5.7	38
81	Does MMP-2 expression and secretion change with increasing serial passage of keratocytes in culture?. Mechanisms of Ageing and Development, 2001, 122, 157-167.	2.2	15
82	Well-defined sulfobetaine-based statistical copolymers as potential antibioadherent coatings. Journal of Biomedical Materials Research Part B, 2000, 52, 88-94.	3.0	92
83	Synthesis and bacterial degradation of an azopolymer. International Journal of Pharmaceutics, 2000, 198, 71-82.	2.6	7
84	Implementation strategies for educational intranet resources. British Journal of Educational Technology, 2000, 31, 47-55.	3.9	9
85	Monitor: molecules and profiles. Drug Discovery Today, 2000, 5, 164-167.	3.2	Ο
86	Monitor: molecules. Drug Discovery Today, 2000, 5, 210-211.	3.2	0
87	Monitor: molecules and profiles. Drug Discovery Today, 2000, 5, 259-261.	3.2	1
88	Monitor: molecules and profiles. Drug Discovery Today, 2000, 5, 301-302.	3.2	0
89	Monitor: molecules and profiles. Drug Discovery Today, 2000, 5, 373-375.	3.2	1
90	Monitor: molecules and profiles. Drug Discovery Today, 2000, 5, 427-429.	3.2	2

6

#	Article	IF	CITATIONS
91	Pharmacogenomics. Drug Discovery Today, 2000, 5, 429-430.	3.2	1
92	Monitor: molecules and profiles. Drug Discovery Today, 2000, 5, 477-480.	3.2	0
93	MOLECULES. Drug Discovery Today, 2000, 5, 528-530.	3.2	0
94	Monitor: molecules and profiles. Drug Discovery Today, 2000, 5, 569-572.	3.2	0
95	Farewell Drug Discovery Today, 2000, 5, 569.	3.2	0
96	Monitor: molecules and profiles. Drug Discovery Today, 2000, 5, 33-34.	3.2	2
97	Monitor: molecules and profiles. Drug Discovery Today, 2000, 5, 85-86.	3.2	0
98	Monitor: molecules and profiles. Drug Discovery Today, 2000, 5, 121-123.	3.2	2
99	Assessing the in vitro cell based ocular compatibility of contact lens materials. Contact Lens and Anterior Eye, 2000, 23, 119-123.	0.8	17
100	Monitor: progress and profiles. Pharmaceutical Science & Technology Today, 2000, 3, 106-110.	0.7	0
101	Monitor: progress and profiles. Pharmaceutical Science & Technology Today, 2000, 3, 146-150.	0.7	0
102	Monitor: progress and profiles. Pharmaceutical Science & Technology Today, 2000, 3, 182-183.	0.7	0
103	Monitor: progress and profiles. Pharmaceutical Science & Technology Today, 2000, 3, 210-215.	0.7	0
104	Monitor: progress and profiles. Pharmaceutical Science & Technology Today, 2000, 3, 257-260.	0.7	0
105	Monitor: PROGRESS. Pharmaceutical Science & Technology Today, 2000, 3, 365-366.	0.7	0
106	Monitor: progress and profiles. Pharmaceutical Science & Technology Today, 2000, 3, 42-45.	0.7	0
107	Monitor: progress and profiles. Pharmaceutical Science & Technology Today, 2000, 3, 70-74.	0.7	0
108	Human keratocyte migration into collagen gels declines with in vitro ageing. Mechanisms of Ageing and Development, 2000, 119, 149-157.	2.2	16

#	Article	IF	CITATIONS
109	Patent focus on drug delivery: June - November 1999. Expert Opinion on Therapeutic Patents, 2000, 10, 273-277.	2.4	0
110	Novel materials to enhance keratoprosthesis integration. British Journal of Ophthalmology, 2000, 84, 640-644.	2.1	17
111	Membrane impermeant antioestrogens discriminate between ligand- and voltage-gated cation channels in NG108-15 cells. Biochimica Et Biophysica Acta - Biomembranes, 2000, 1509, 229-236.	1.4	11
112	Intranet-based learning:a one-year study of student utilisation. Journal of Computer Assisted Learning, 1999, 15, 269-278.	3.3	9
113	Hurdles to successful implementation of "Learning Trees― British Journal of Educational Technology, 1999, 30, 61-64.	3.9	2
114	Monitor: molecules and profiles. Drug Discovery Today, 1999, 4, 39-41.	3.2	1
115	Monitor: molecules and profiles. Drug Discovery Today, 1999, 4, 93-94.	3.2	Ο
116	Monitor. Drug Discovery Today, 1999, 4, 139-140.	3.2	1
117	Monitor: molecules and profiles. Drug Discovery Today, 1999, 4, 186.	3.2	1
118	Monitor: molecules and profiles. Drug Discovery Today, 1999, 4, 289-291.	3.2	0
119	Monitor: molecules and profiles. Drug Discovery Today, 1999, 4, 333-336.	3.2	Ο
120	Antitumour activity of thioester derivatives of leinamycin. Drug Discovery Today, 1999, 4, 384-386.	3.2	0
121	Monitor: molecules and profiles. Drug Discovery Today, 1999, 4, 440-442.	3.2	Ο
122	Monitor: molecules and profiles. Drug Discovery Today, 1999, 4, 480-481.	3.2	0
123	Monitor: molecules and profiles. Drug Discovery Today, 1999, 4, 530-531.	3.2	Ο
124	Monitor: molecules and profiles. Drug Discovery Today, 1999, 4, 568-570.	3.2	0
125	Monitor: molecules and profiles. Drug Discovery Today, 1999, 4, 238-239.	3.2	0
126	AAPS meeting builds bridges for the new millennium. Pharmaceutical Science & Technology Today, 1999, 2, 3-4.	0.7	0

#	Article	IF	CITATIONS
127	Monitor: progress and profiles. Pharmaceutical Science & Technology Today, 1999, 2, 121-125.	0.7	Ο
128	Monitor: progress and profiles. Pharmaceutical Science & Technology Today, 1999, 2, 171-173.	0.7	0
129	Monitor: progress and profiles. Pharmaceutical Science & Technology Today, 1999, 2, 381-383.	0.7	0
130	Monitor: progress and profiles. Pharmaceutical Science & Technology Today, 1999, 2, 414-417.	0.7	0
131	Monitor: progress and profiles. Pharmaceutical Science & Technology Today, 1999, 2, 493-495.	0.7	0
132	A Standard Strain of Human Ocular Keratocytes. Ophthalmic Research, 1999, 31, 33-41.	1.0	12
133	Monitor: molecules and profiles. Drug Discovery Today, 1998, 3, 43-46.	3.2	1
134	Monitor: Molecules and profiles. Drug Discovery Today, 1998, 3, 141-142.	3.2	1
135	Monitor: molecules and profiles. Drug Discovery Today, 1998, 3, 189-191.	3.2	0
136	Monitor: molecules and profiles. Drug Discovery Today, 1998, 3, 239-240.	3.2	0
137	Monitor: molecules and profiles. Drug Discovery Today, 1998, 3, 295-296.	3.2	1
138	Monitor: molecules and profiles. Drug Discovery Today, 1998, 3, 350-351.	3.2	1
139	Monitor: molecules and profiles. Drug Discovery Today, 1998, 3, 480-482.	3.2	3
140	Monitor: molecules and profiles. Drug Discovery Today, 1998, 3, 522-524.	3.2	0
141	Emerging molecular targets. Drug Discovery Today, 1998, 3, 525.	3.2	1
142	Monitor: molecules and profiles. Drug Discovery Today, 1998, 3, 561-562.	3.2	0
143	Monitor: progress and profiles. Pharmaceutical Science & Technology Today, 1998, 1, 83-86.	0.7	0
144	Monitor: progress and profiles. Pharmaceutical Science & Technology Today, 1998, 1, 136-139.	0.7	0

#	Article	IF	CITATIONS
145	Monitor: progress and profiles. Pharmaceutical Science & Technology Today, 1998, 1, 174-178.	0.7	Ο
146	Monitor: progress and profiles. Pharmaceutical Science & Technology Today, 1998, 1, 224-227.	0.7	0
147	Monitor: progress and profiles. Pharmaceutical Science & Technology Today, 1998, 1, 277-279.	0.7	0
148	Monitor: progress and profiles. Pharmaceutical Science & Technology Today, 1998, 1, 317-320.	0.7	0
149	Monitor: progress and profiles. Pharmaceutical Science & Technology Today, 1998, 1, 357-360.	0.7	0
150	Biomaterials—where are we going?. Pharmaceutical Science & Technology Today, 1998, 1, 363-364.	0.7	1
151	A mechanistic investigation into the microbial chiral inversion of 2-arylpropionic acids using deuterated derivatives of 2-phenylpropionic acid. Enzyme and Microbial Technology, 1998, 22, 281-287.	1.6	15
152	The stereo inversion of 2-arylpropionic acid non-steroidal anti-inflammatory drugs and structurally related compounds by Verticillium lecanii. Journal of Applied Microbiology, 1998, 85, 155-163.	1.4	12
153	Glaucoma drainage devices; past, present, and future. British Journal of Ophthalmology, 1998, 82, 1083-1089.	2.1	154
154	Different Kinetics of Senescence in Human Fibroblasts and Peritoneal Mesothelial Cells. Experimental Cell Research, 1997, 236, 355-358.	1.2	56
155	Monitor: molecules and profiles. Drug Discovery Today, 1997, 2, 122-124.	3.2	Ο
156	Stereochemistry: handling interactions. Drug Discovery Today, 1997, 2, 127.	3.2	3
157	Monitor: Molecules and profiles. Drug Discovery Today, 1997, 2, 206.	3.2	Ο
158	Novel pyranoxanthones. Drug Discovery Today, 1997, 2, 301-306.	3.2	1
159	Modifying the drug discovery/drug development paradigm. Drug Discovery Today, 1997, 2, 397-398.	3.2	9
160	New delivery systems for macromolecules. Drug Discovery Today, 1997, 2, 402-404.	3.2	0
161	Investigations into the azo reducing activity of a common colonic microorganism. International Journal of Pharmaceutics, 1997, 157, 61-71.	2.6	97
162	Indirect enantiomeric separation of 2-arylpropionic acids and structurally related compounds by reversed phase HPLC. Journal of Pharmaceutical and Biomedical Analysis, 1997, 15, 1765-1774.	1.4	14

#	Article	IF	CITATIONS
163	Case histories in drug discovery. Drug Discovery Today, 1996, 1, 90-91.	3.2	Ο
164	A comparison of carboxylate salts as liposomal cryoprotectants. International Journal of Pharmaceutics, 1996, 131, 257-262.	2.6	12
165	Penochalasins. Drug Discovery Today, 1996, 1, 217-217.	3.2	0
166	Potential atypical antipsychotic agents. Drug Discovery Today, 1996, 1, 217-218.	3.2	0
167	Neuronal calcium channel blocker. Drug Discovery Today, 1996, 1, 218-218.	3.2	0
168	AMPA receptor inhibitors. Drug Discovery Today, 1996, 1, 218-218.	3.2	0
169	Nonpeptide somatostatin ligand. Drug Discovery Today, 1996, 1, 218-218.	3.2	0
170	Balanced angiotensin II receptor antagonist. Drug Discovery Today, 1996, 1, 218-218.	3.2	0
171	Enantioselective total synthesis of (+)-duocarmycin A. Drug Discovery Today, 1996, 1, 219-219.	3.2	1
172	Total synthesis of antifungal FR-900848. Drug Discovery Today, 1996, 1, 219-219.	3.2	0
173	Selective cleavage of ketals and acetals. Drug Discovery Today, 1996, 1, 219-219.	3.2	0
174	Synthesis of pyrrolo [2,1][1,4]benzodiazepie antibiotics. Drug Discovery Today, 1996, 1, 219-219.	3.2	0
175	Synthesis of fused 1,2,4-thiadiazoles. Drug Discovery Today, 1996, 1, 220-220.	3.2	0
176	Squalene synthase inhibitors. Drug Discovery Today, 1996, 1, 82.	3.2	0
177	Chiral Europe '95. Drug Discovery Today, 1996, 1, 7-7.	3.2	Ο
178	Demonstration of the chiral inversion of ibuprofen by Verticillium lecanii in non-growing cultures. Letters in Applied Microbiology, 1996, 23, 417-420.	1.0	7
179	Chiral inversion of 2â€phenylpropionic acid by Cordyceps militaris. Journal of Applied Bacteriology, 1996, 81, 242-250.	1.1	10
180	Azopolymers: a means of colon specific drug delivery?. International Journal of Pharmaceutics, 1994, 106, 255-260.	2.6	31

#	Article	IF	CITATIONS
181	A comparative study of the cryopreservation of human erythrocytes, ghosts and liposomes. Biochemical Society Transactions, 1988, 16, 354-354.	1.6	2